Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04080778 · ClinicalTrials.gov registry record · NA

Magnetic Seizure Therapy in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD)

A NA study of Bipolar Disorder, sponsored by Joao L. DeQuevedo.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT04080778 is a NA study of Bipolar Disorder that is actively recruiting participants, run by Joao L. DeQuevedo. The registered enrollment target is 60 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04080778, a NA study of Bipolar Disorder, is actively recruiting participants, sponsored by Joao L. DeQuevedo.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the efficacy and side effects magnetic seizure therapy (MST) and electroconvulsive therapy (ECT) in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD).

Conditions Studied

Interventions

  • DEVICE magnetic seizure therapy (MST)
  • DEVICE electroconvulsive therapy (ECT)

Study Locations (1)

Texas

  • The University of Texas Health Science Center at Houston - Houston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-08-24
Est. Completion 2027-12-30
Phase NA

Sponsor

Joao L. DeQuevedo

1 total trials

What the Registry Record Tells You About NCT04080778

The ClinicalTrials.gov registry entry for NCT04080778 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (82% lower). The listed sponsor is Joao L. DeQuevedo, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which magnetic seizure therapy (MST) is the first listed.

NCT04080778 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04080778 about?

NCT04080778 is a clinical study titled "Magnetic Seizure Therapy in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD)". The purpose of this study is to compare the efficacy and side effects magnetic seizure therapy (MST) and electroconvulsive therapy (ECT) in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD).

What is the current status of trial NCT04080778?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-08-24. Estimated completion is 2027-12-30.

What conditions does trial NCT04080778 study?

This clinical trial studies the following conditions: Bipolar Disorder.

What interventions are being tested in trial NCT04080778?

The interventions under investigation include: magnetic seizure therapy (MST) (DEVICE), electroconvulsive therapy (ECT) (DEVICE).

Who is sponsoring clinical trial NCT04080778?

This trial is sponsored by Joao L. DeQuevedo, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04080778 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bipolar Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.